TITLE

Bayer wins Novartis pesticide suit

AUTHOR(S)
SCOTT, ALEX
PUB. DATE
January 1999
SOURCE
Chemical Week;1/6/1999, Vol. 161 Issue 1, p45
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports that Bayer company has won the suit brought by Novartis company regarding Bayer's patent on thiamethoxam insecticides. Rulings of the European Patent Office (EPO); Argument of Novartis on Bayer's patent on thiamethoxams.
ACCESSION #
1453677

 

Related Articles

  • Broad claim construction leads to invalidity of Novartis's patent for EXELON Alzheimer's patch. Moore, Sebastian; Pead, Grace // Journal of Intellectual Property Law & Practice;Sep2015, Vol. 10 Issue 9, p653 

    The article discusses the court case Novartis AG & Others versus Focus Pharmaceuticals Ltd. & Others wherein the Patents Court of England and Wales ruled on April 27, 2015 that the patent of Novartis covering its EXELON rivastigmine transdermal patch to treat Alzheimer's disease is invalid.

  • In case of German company's request for evidence under 28 U.S.C. Section 1782 for use in Spanish court action, Third Circuit holds that Section 1782 incorporates Federal Rules of Civil Procedur...  // International Law Update;May99, Vol. 5, p53 

    Focuses on German company Bayer AG application filed with United States courts seeking the production of unredacted versions of documents for use in a Spanish proceeding against Betachem Inc. Details of the patent infringement case filed by Bayer against Barr Laboratories and Betachem Inc.; US...

  • TRIALS AND TRIPS-ULATIONS: INDIAN PATENT LAW AND NOVARTIS AG V. UNION OF INDIA. Lee, Linda L. // Berkeley Technology Law Journal;2008 Annual Review, Vol. 23 Issue 1, p281 

    The article focuses on the emerging debate regarding intellectual property rights in India. Novartis AG v. Union of India has grabbed the attention of multinational pharmaceuticals concerned about the generic market and the international community concerned about India's compliance with the...

  • Unified vision. Campbell, Douglas // Lawyer;1/3/2011, Vol. 25 Issue 1, p29 

    The article reports on the issue of jurisdiction of hearing the lawsuit filed by Johnson and Johnson against Novartis AG for patent infringement over contact lenses in all over Europe. An issue was brought over the varying decision if judges are to hear patent cases and the question on which...

  • Foreign Infringement in Imported Products. Centanni, Jillian A. // Intellectual Property Litigation;Spring2013, Vol. 24 Issue 3, p14 

    The article focuses the Process Patents Amendment Act which regulates patent infringement on importation of products in the U.S. It argues on the statutory basis of the Section 271 of Title 35 of the U.S. Code for intellectual property of imported products. It also mentions several court cases...

  • Court Denies En Banc Review in "Pay for Delay" Generic Drug Case. Dailing, Paul // InsideCounsel;Nov2010, p10 

    The article discusses the court case Arkansas Carpenters Health and Welfare Fund v. Bayer AG wherein the U.S. Court of Appeals 2nd Circuit decided in September 2010 not to reconsider en banc a ruling that pay-to-delay payments for generic drug, antibiotic ciprofloxacin hydrochloride are...

  • Novartis Loses Discrimination Suit.  // Pharmaceutical Representative;Jun2010, Vol. 40 Issue 6, p9 

    The article reports on the decision of the federal jury in New York regarding the gender discrimination lawsuit against Novartis AG.

  • BAYER AG V. HOUSEY PHARMACEUTICALS, INC.  // Berkeley Technology Law Journal;Annual Review 2002, Vol. 17 Issue 1, p145 

    Focuses on the scope of the infringement claims of Bayer AG. Decision of the district court over the issue; Applicability of the statute on patents claiming screening methods; Inclusions of the collective ICT patents.

  • Gleevec loses Indian patent battle. Jayaraman, Killugudi // Nature Biotechnology;May2013, Vol. 31 Issue 5, p371 

    The article presents a court case wherein the Supreme Court in India has rejected the extension of patent protection filed by Novartis for its leukemia drug Gleevec or Glivec (imatinib).

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics